The once-monthly drug is still under study but could provide added convenience and another option for patients.

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained weight loss of up to 20% in adults with obesity, with or without type 2 diabetes,

Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped participants in a phase 2 clinical trial shed about 20% of their body weight over a year,